Trials / Completed
CompletedNCT01508416
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma: a Multicentric Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 71 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with Multiple Myeloma (MM) are at increased risk of venous thromboembolic event, especially in newly diagnosed patients and during induction treatment with thalidomide in combination with dexamethasone. This association was mainly heightened during the 3 first months of chemotherapy. Several coagulation abnormalities have been described. Laboratory tests measuring the overall thrombophilic tendency might be useful to assess thrombosis risk. The aim of this study is to compare thrombin generation by calibrated automated thrombogram during the 3 first cycles of chemotherapy in patients with newly diagnosed MM.
Conditions
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2014-12-01
- Completion
- 2015-06-01
- First posted
- 2012-01-12
- Last updated
- 2015-07-28
Locations
5 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01508416. Inclusion in this directory is not an endorsement.